LifeMD is the publicly traded generalist: a telehealth platform whose weight program leans into insurance navigation and brand-drug access, with manufacturer-channel integrations reported through the 2025 direct-pharmacy era. Its own fee stack and all-in totals are the pending part. Queue #13.
First-party read, September 17, 2026
What the program’s own pages print, recorded on the date shown; nothing below is estimated, and a price the page does not print is listed without a rank. The all-in figures add the program fee to the medication price the page prints.
| Program fee | $39 for the first month of care, then $149 a month “with the flexibility to cancel anytime”; medication cost not included. |
|---|---|
| Brand medication | “Wegovy Pen Starting At Just $199” — about $348 a month all-in with the fee; “Zepbound Vial Starting At $299” — about $448 all-in. Both rise with the dose. |
| Compounded medication | The page says a provider may prescribe compounded medication “in certain situations, where clinically appropriate” and prints no compounded price. An earlier record of $129/month + $49 (semaglutide) and $179/month + $49 (tirzepatide), read 2026-05-25, is withdrawn as no longer printed — listed, not ranked. |
| Insurance | “As low as $25 copay” for branded GLP-1s with coverage. |
| Cancellation / guarantee | Cancel anytime; “Lose 10% of your weight or your money back” (terms apply). |
| Shipping, pharmacies, states | Not stated on the page read. |
| Read | 2026-09-17 — https://lifemd.com/weight-management |
The model
The structural pitch is legitimacy-by-infrastructure: licensed clinicians across states, insurance billing muscle, and reported plumbing into the manufacturers’ cash channels as they opened. As a public company it also publishes more about itself than most of this market — filings beat marketing pages for candor.
The questions are the brand-lane classics: what LifeMD’s layer costs beside going direct to a manufacturer pharmacy yourself; how much of the advertised program is care versus coordination; and where compounded options fit, if at all, in its current posture. U.S. News-rated visibility (2026, per the release) drives comparison demand; verification, not visibility, fills our ledger.
The diligence script for LifeMD
In writing: the all-in monthly at your maintenance dose including every platform fee, quoted beside the same drug via the manufacturer’s own channel; insurance-navigation specifics (who files the PA, what the appeal path is); the current compounded policy with legal basis if any; and visit cadence with prescriber credentials. A coordination layer earns its fee by beating DIY — make it show the math.
Where LifeMD fits
Fits insured readers who want the paperwork done and cash buyers who value brand certainty with hand-holding. Poor fit where the verified flat-rate lane already beats the coordinated brand total — which is exactly the comparison the calculator forces.
Queue position and how it moves
LifeMD sits at position 13 of 17 in the public verification queue (added 2026-08 with the U.S. News-rated field expansion). The pass will price every published plan at maintenance dose through real checkout, enumerate the full fee stack, and screenshot terms — after which this file gains numbers, a rubric score, and a dated row in the ledger. Documentation sent via the verification channel accelerates scheduling, never the standard.
Library files that matter here
For this model specifically: the navigation playbook to hold theirs against; when the PA fails; layer-versus-DIY math.
FAQ
Does LifeMD prescribe brand-name GLP-1s? Brand access with insurance and manufacturer-channel routing is the advertised core — confirm current specifics and every platform fee in writing; the pending audit will do the same. Is LifeMD cheaper than going to the manufacturer pharmacy directly? Same drugs underneath — the question is what the coordination layer adds in fees versus value; two written quotes settle it in minutes.
Side-by-side files
No head-to-heads feature LifeMD yet — pairs are built as verification and reader demand warrant, under the comparison hub’s no-duplicate rules. Meanwhile: the ranked field and the model map place it in context.
The bottom line
Infrastructure and filings are real advantages; whether the layer prices fairly is queue #13’s job — and your two-quote test’s, today.